Journal Article Review Ppublish
PubMed: 40391706 DOI: 10.1002/advs.202505067
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.
Adv Sci (Weinh) 12(30):e05067
Authors: Xiangqi Chen, Chuan Wu, Fei Tang, Jingyue Zhou, Li Mo, Yanping Li, Jinhan He
Affiliations
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China.
Abstract
Fibrosis, characterized by abnormal deposition of structural proteins, is a major cause of tissue dysfunction in chronic diseases. The disease burden associated with progressive fibrosis is substantial, and currently approved drugs are unable to effectively reverse it. Immune cells are increasingly recognized as crucial regulators in the pathological process of fibrosis by releasing effector molecules, such as cytokines, chemokines, extracellular vesicles, metabolites, proteases, or intercellular contact. Therefore, targeting the immune microenvironment can be a potential strategy for fibrosis reduction and reversion. This review summarizes the recent advances in the understanding of the immune microenvironment in fibrosis including phenotypic and functional transformations of immune cells and the interaction of immune cells with other cells. The novel opportunities for the discovery and development of drugs for immune microenvironment remodeling and their associated challenges are also discussed.
MeSH
Cells, Fibrosis, Biomedical Research, Pharmaceutical Preparations, Therapeutics
Cited by
- The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis. Adv Sci (Weinh), 2025